Cue Biopharma, Inc. Payments to Acquire Marketable Securities
Cue Biopharma, Inc. (CUE) reported Payments to Acquire Marketable Securities of $16.29 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-03-16
- Cue Biopharma, Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $0.00.
- Cue Biopharma, Inc. payments to acquire marketable securities for the quarter ending 2024-12-31 was $0.00.
- Cue Biopharma, Inc. payments to acquire marketable securities for fiscal 2025 was $16.29M.
- Cue Biopharma, Inc. payments to acquire marketable securities for fiscal 2024 was $0.00.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $16.29M 10-K · filed 2026-03-16 | |
| 2025-09-30 | $16.29M 10-Q · filed 2025-11-12 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $0.00 10-K · filed 2026-03-16 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |